Plain-English translation of NCT05562947 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new way to treat neovascular age-related macular degeneration (nAMD), a serious eye condition that causes vision loss. Researchers are comparing two approaches: an implanted device that delivers ranibizumab slowly over 24 weeks, versus regular eye injections every 4 weeks. The goal is to see if the implant works as well as or better than injections while being easier for patients to manage.
People with nAMD currently need frequent eye injections—sometimes every month—to prevent blindness. This trial is exploring whether a surgically implanted device that requires fewer refills could provide better treatment while reducing the burden of frequent doctor visits and injections.
If you are assigned to the implant group, you will have a small surgical procedure on Day 1 to place the device in your eye, followed by monthly visits for the first two years. You will return every 24 weeks to have the implant refilled with fresh medicine. If you are assigned to the injection group, you will receive injections every 4 weeks for about a year, then switch to the implant and follow the same schedule as the first group. The study continues for several years with visits becoming less frequent over time.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
China